Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Deutsche Boerse AG  >  GlaxoSmithKline    GS7   GB0009252882

GLAXOSMITHKLINE (GS7)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

GlaxoSmithKline: Positive Results for ViiV Healthcare's HIV Studies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2018 | 08:45am CET

By Maryam Cockar

GlaxoSmithKline said Thursday that its subsidiary, ViiV Healthcare Ltd, has reported positive phase 3 studies for the dolutegravir and lamivudine drugs, demonstrating the ability to control HIV with a two-drug regimen.

GSK said that the GEMINI 1 and 2 studies demonstrated a similar efficacy of a two-drug regimen compared with the standard three-drug regimen in patients that have never undergone treatment for a specific illness.

"The GEMINI studies demonstrate the potency, safety and tolerability of the dolutegravir plus lamivudine combination. They affirm our two-drug regimen strategy, and reinforce our belief that many patients can control their disease with two drugs instead of three or more. Importantly, the studies show that this two-drug regimen could be an option for treatment naive patients and can support a broad range of patients living with HIV around the world," said John Pottage, chief scientific and medical officer of ViiV Healthcare.

GSK said the GEMINI studies are part of ViiV Healthcare's clinical-trial program "for two-drug regimens that seeks to address long-term toxicity concerns of people living with HIV by reducing the number of medicines used in their treatment".

Specialist HIV company ViiV Healthcare is majority owned by GSK, with Pfizer and Shionogi & Co. (4507.TO).

Write to Maryam Cockar at maryam.cockar@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 0.87% 1582.2 Delayed Quote.18.61%
GLAXOSMITHKLINE 0.45% 17.88 Delayed Quote.18.66%
PFIZER -1.47% 43.53 Delayed Quote.21.98%
SHIONOGI & CO LTD -1.28% 7582 End-of-day quote.22.53%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
11/20GLAXOSMITHKLINE : Access to Medicine Index 2018 media statement
PU
11/20BIG PHARMA LEAVES BIG GAPS : drugmakers urged to do more for poor
RE
11/19GLAXOSMITHKLINE : Looks to Expand Nucala Indication in the U.S.
DJ
11/19GLAXOSMITHKLINE : GSK submits US regulatory filing to expand the use of Nucala i..
PU
11/16GLAXOSMITHKLINE : ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU ..
PU
11/15British stocks battered on Brexit deal backlash, exporters gain
RE
11/15GLAXOSMITHKLINE : Ex-dividend day for interim dividend
FA
11/14GLAXOSMITHKLINE : RIP1 kinase identified as promising therapeutic target in panc..
AQ
11/12GLAXOSMITHKLINE : Once-daily Trelegy Ellipta gains expanded COPD indication in E..
AQ
11/12GLAXOSMITHKLINE : Blocklisting Application
PU
More news
Financials (GBP)
Sales 2018 30 482 M
EBIT 2018 8 404 M
Net income 2018 3 433 M
Debt 2018 21 916 M
Yield 2018 5,12%
P/E ratio 2018 22,67
P/E ratio 2019 17,33
EV / Sales 2018 3,26x
EV / Sales 2019 3,16x
Capitalization 77 484 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 16,4  GBP
Spread / Average Target 5,3%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE18.66%99 398
JOHNSON & JOHNSON4.49%391 542
PFIZER20.13%252 358
NOVARTIS5.92%222 056
ROCHE HOLDING LTD.0.00%214 508
MERCK AND COMPANY35.69%197 785